CD8A and ovarian carcinoma: Based on analyses of biopsy samples acquired before treatment with GEN1046, the PD-L1 tumor proportion scores (TPS) were 1% in the patient with NSCLC and 0.5% in the patient with ovarian cancer; the PD-L1 combined positive scores (CPS) were 5 and 12; 4-1BB was expressed in 147 and 26 cells/mm2; and the densities of CD8+ T cells in the TME were 385 and 518 cells/mm2, respectively (Supplementary Fig. S4A and S4B).